We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




POC D-Dimer Assays Compared with Standard Method

By LabMedica International staff writers
Posted on 18 Apr 2012
D-dimer assays are effective for the exclusion of deep-vein thrombosis (DVT), but point-of-care (POC) D-dimer assays have only recently been fully evaluated.

Measurement of D-dimer has been enabled after the development of monoclonal antibodies used in enzyme-linked immunosorbent assays (ELISAs) which have a sensitivity of 98% with a negative predictive value of greater than 95%. More...


However, ELISAs are complicated, time-consuming, and labor intensive and could generally only be performed in laboratories during daytime working hours. Scientists at the Karolinska Institutet, (Stockholm, Sweden) compared five POC D-dimer assays with their routine Tinaquant fully automated quantitative immunoturbidimetric assay that utilizes microlatex particles coated with anti-human D-dimer monoclonal antibody. They tested 60 samples from patients with suspected DVT. The cut-off value was 0.25 µg/mL of D-dimer, which corresponds to 0.5 µg/mL of fibrinogen equivalent units (FEU).

The five POC assays tested were the Pathfast D-dimer chemiluminescent enzyme immunoassay (CLEIA) magnetic filtration (Mitsubishi Chemical; Tokyo, Japan); the Cardiac D-dimer sandwich method, using monoclonal gold-labeled antibodies which like the standard Tinaquant assay is from Roche Diagnostics, (Mannheim, Germany); the Vidas D-dimer, a sandwich method, using monoclonal antibodies with fluorescence detection (BioMérieux; Marcy l’Etoile, France); the Stratus CS D-dimer sandwich method using monoclonal antibodies radial partition (Siemens Diagnostics; Marburg, Germany); and the NycoCard D-dimer sandwich method, which uses monoclonal antibodies gold colloids (Nycomed Pharma; Oslo, Norway).

The results of the study showed that using 0.5 µg/mL as a cut-off value, four samples tested negative with Tinaquant were positive with Pathfast. There were no Tinaquant-positive samples tested negative with Pathfast, while the overall agreement was very good. Four samples were discrepant between Tinaquant and Cardiac with the lower cut-off of 0.4 µg/mL. Eight samples of 27 were negative with NycoCard although they were positive with the standard Tinaquant assay. The agreement with Tinaquant was excellent for both Vidas and Stratus.

The authors concluded that that the four of five tested POC D-dimer assays have an analytical profile comparable to that obtained using standard laboratory assay, while three of them may be used for rapid bed-side analysis. Their evaluation indicates that Pathfast D-dimer, Cardiac D-dimer and Stratus CS D-dimer can be used for rapid bed-side analysis and offers a possibility to adequately rule out DVT in outpatients within minutes after admission. The study was published on April 5, 2012, in the International Journal of Laboratory Hematology.

Related Links:

Karolinska Institutet
Mitsubishi Chemical
Roche Diagnostics




New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Automatic Hematology Analyzer
LABAS F9000
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Microbiology

view channel
Image: The groundbreaking salmonella antimicrobial resistance prediction platform has demonstrated 95% accuracy (Photo courtesy of Yujie You et al., DOI: 10.1016/j.eng.2025.01.013)

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance

Antimicrobial-resistant Salmonella strains are a growing public health concern due to the overuse of antimicrobials and the rise of genetic mutations. Accurate prediction of resistance is crucial for effective... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.